Patent · US Active

Antibodies and nucleotide sequences, and uses thereof

US12291569B2 · kind B2 · utility

0Cited by

1References

8Claims

0Family size

Assignee

BIOINVENT INTERNATIONAL AB · SE

Inventors

Björn Frendéus · Landskrona, SE
Ingrid Teige · Lund, SE
Monika SEMMRICH · Malmö, SE
Linda MÅRTENSSON · Bjärred, SE
Petra HOLMKVIST · Strada a scorrimento veloce Trapani-Marsala, SE

Key dates

Filing date	Sep 3, 2019
Grant date	May 6, 2025
Priority date	—
Expiry date	Apr 19, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/24143
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described are novel anti-CTLA-4 antibody molecules and nucleotide sequences and expression vectors, such as viruses, encoding such antibody molecules. The novel antibody molecules are Treg depleting antibody molecules, and they have an improved depleting effect on CTLA-4 positive cells, such as Tregs, compared to ipilimumab. Described is also the use of such antibody molecules or nucleotide sequences or viruses in medicine, such as in the treatment of cancer, such as solid tumours.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.